Todd M Brusko,
Professor
About Todd M Brusko
Additional Positions:
Assistant Dean of Basic Research
2024 – Current
·
College of Medicine
Teaching Profile
Courses Taught
2015,2017-2019,2019-2024
GMS6383 Current Topics in Immunotherapy
2019
GMS6234 Introduction to phylodynamics: A practical approach to molecular phylogenetics of pathogens
2018
GMS7980 Research for Doctoral Dissertation
2018
GMS7979 Advanced Research
2018
VME7980 Research for Doctoral Dissertation
2018
BME7980 Research for Doctoral Dissertation
2014,2017
GMS6335 Advanced Stem Cell Biology: Tissue Engineering
2014-2016
GMS6140 Principles of Immunology
2013
GMS5905 Special Topics in Biomedical Sciences
2012
GMS6382 Special Topics in Immunology
2024
GMS6905 Independent Studies in Medical Sciences
Research Profile
Dr. Todd Brusko is appointed as a Professor in the Department of Pathology at the University of Florida College of Medicine. He currently serves as the Research Director of the UF Diabetes Institute. The research interests of the Brusko Laboratory are centrally themed around understanding the mechanisms by which the immune system maintains a state of control, often referred to as immunological tolerance. This includes studies of the innate and adaptive immune system, with a particular focus on the TCR repertoire and costimulation of T cells and regulatory T cells. A portion of the Brusko lab is dedicated to understanding the genetic variants controlling these processes, as well as identifying the mechanisms at play in individuals who develop immune-mediated diseases. As evidence of this, Dr. Brusko has previously published over 100 studies reporting cellular immune defects in patients with type 1 diabetes (T1D), lupus, sepsis, and cancer and investigated cellular immune mechanisms and biological basis of such diseases. A major goal of the laboratory is to create a basic understanding of immune system development over the human lifespan in peripheral blood and within central and peripheral immune tissues. Toward this goal, the Brusko Laboratory is involved in major projects to profile immune system function in type 1 diabetes through the Network for Pancreatic Organ donors with Diabetes program (JDRF – nPOD), the thymus and lymphatics in the Human Biomolecular Atlas Program (HuBMAP –NIH Directors Fund), NIH Human Islet Research Network programs (CHIB and HPAP), and the Human Atlas for Neonatal and Developmental Early Life – Immunity (HANDEL-I) program (Helmsley Charitable Trust). These efforts are enabled through the establishment of robust precision medicine genotyping, single cell epigenetics and transcriptomics, immune repertoire analysis, and high parameter spectral flow cytometry within the UF Center for Immunology and Transplantation (CIT). Collectively, these efforts provide a foundational framework for defining immunity in health and deviations in PBMCs and peripheral tissue immune cells indicative of disease states for the development of biomarkers and targeted immune interventions.
Areas of Interest
- Immunology of Type 1 diabetes
- Phenotype genotype correlation in perinatal pathology
- Prevention and intervention trials in Type 1 diabetes
- Type 1 Diabetes
Open Researcher and Contributor ID (ORCID)
0000-0003-2878-9296
Publications
2024
A global view of T cell metabolism in systemic lupus erythematosus.
Frontiers in immunology.
15
[DOI] 10.3389/fimmu.2024.1371708.
[PMID] 38756769.
2024
Data-driven selection of analysis decisions in single-cell RNA-seq trajectory inference.
Briefings in bioinformatics.
25(3)
[DOI] 10.1093/bib/bbae216.
[PMID] 38725155.
2024
Diabetes Study of Children of Diverse Ethnicity and Race: Study design.
Diabetes/metabolism research and reviews.
40(3)
[DOI] 10.1002/dmrr.3744.
[PMID] 37888801.
2024
Human γδ T cells in diverse tissues exhibit site-specific maturation dynamics across the life span
Science Immunology.
9(96)
[DOI] 10.1126/sciimmunol.adn3954.
[PMID] 38848342.
2024
Inhibition of CD226 Co-Stimulation Suppresses Diabetes Development in the NOD Mouse by Augmenting Tregs and Diminishing Effector T Cell Function.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.07.16.603756.
[PMID] 39071293.
2024
Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes.
Diabetes care.
47(2):285-289
[DOI] 10.2337/dc23-1750.
[PMID] 38117469.
2024
NADPH Oxidase 2–Derived Reactive Oxygen Species Promote CD8+ T Cell Effector Function
The Journal of Immunology.
212(2):258-270
[DOI] 10.4049/jimmunol.2200691.
[PMID] 38079221.
2024
The immunology of type 1 diabetes.
Nature reviews. Immunology.
24(6):435-451
[DOI] 10.1038/s41577-023-00985-4.
[PMID] 38308004.
2024
The post-septic peripheral myeloid compartment reveals unexpected diversity in myeloid-derived suppressor cells.
Frontiers in immunology.
15
[DOI] 10.3389/fimmu.2024.1355405.
[PMID] 38720891.
2023
A genomic data archive from the Network for Pancreatic Organ donors with Diabetes
Scientific Data.
10(1)
[DOI] 10.1038/s41597-023-02244-6.
[PMID] 37237059.
2023
Biomaterials‐based nanoparticles conjugated to regulatory T cells provide a modular system for localized delivery of pharmacotherapeutic agents
Journal of Biomedical Materials Research Part A.
111(2):185-197
[DOI] 10.1002/jbm.a.37442.
[PMID] 36082558.
2023
Data-driven selection of analysis decisions in single-cell RNA-seq trajectory inference.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.12.18.572214.
[PMID] 38187768.
2023
DHCR7 Expression Predicts Poor Outcomes and Mortality from Sepsis.
Research square.
[DOI] 10.21203/rs.3.rs-2500497/v1.
[PMID] 36778468.
2023
DHCR7 Expression Predicts Poor Outcomes and Mortality From Sepsis.
Critical care explorations.
5(6)
[DOI] 10.1097/CCE.0000000000000929.
[PMID] 37332366.
2023
Human immune phenotyping reveals accelerated aging in type 1 diabetes
JCI Insight.
8(17)
[DOI] 10.1172/jci.insight.170767.
[PMID] 37498686.
2023
Immune engineered extracellular vesicles to modulate T cell activation in the context of type 1 diabetes
Science Advances.
9(22)
[DOI] 10.1126/sciadv.adg1082.
[PMID] 37267353.
2023
Induction of bronchus-associated lymphoid tissue is an early life adaptation for promoting human B cell immunity
Nature Immunology.
24(8):1370-1381
[DOI] 10.1038/s41590-023-01557-3.
[PMID] 37460638.
2023
Insulin-like Growth Factor-1 Synergizes with IL-2 to Induce Homeostatic Proliferation of Regulatory T Cells
The Journal of Immunology.
211(7):1108-1122
[DOI] 10.4049/jimmunol.2200651.
[PMID] 37594278.
2023
Milder loss of insulin-containing islets in individuals with type 1 diabetes and type 2 diabetes-associated TCF7L2 genetic variants
Diabetologia.
66(1):127-131
[DOI] 10.1007/s00125-022-05818-y.
[PMID] 36282337.
2023
Modeling cell-mediated immunity in human type 1 diabetes by engineering autoreactive CD8+ T cells.
Frontiers in immunology.
14
[DOI] 10.3389/fimmu.2023.1142648.
[PMID] 37325626.
2023
Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes
JCI Insight.
8(16)
[DOI] 10.1172/jci.insight.161812.
[PMID] 37432736.
2023
Site-specific development and progressive maturation of human tissue-resident memory T cells over infancy and childhood.
Immunity.
56(8):1894-1909.e5
[DOI] 10.1016/j.immuni.2023.06.008.
[PMID] 37421943.
2023
Treg-Specific CD226 Deletion Reduces Diabetes Incidence in NOD Mice by Improving Regulatory T-Cell Stability
Diabetes.
72(11):1629-1640
[DOI] 10.2337/db23-0307.
[PMID] 37625150.
2022
Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.
European journal of immunology.
52(3):372-388
[DOI] 10.1002/eji.202049067.
[PMID] 35025103.
2022
Human CD4+CD25+CD226- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4+CD25+CD127lo/- Tregs for Adoptive Cell Therapy.
Frontiers in immunology.
13
[DOI] 10.3389/fimmu.2022.873560.
[PMID] 35693814.
2022
Improving the Prediction of Type 1 Diabetes Across Ancestries
Diabetes Care.
45(3):e48-e50
[DOI] 10.2337/dc21-1254.
[PMID] 35043156.
2021
A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes.
Critical care (London, England).
25(1)
[DOI] 10.1186/s13054-021-03757-5.
[PMID] 34535154.
2021
A Novel Single Cell RNA-seq Analysis of Non-Myeloid Circulating Cells in Late Sepsis.
Frontiers in immunology.
12
[DOI] 10.3389/fimmu.2021.696536.
[PMID] 34484194.
2021
Autoreactive T cell receptors with shared germline-like α chains in type 1 diabetes
JCI Insight.
6(22)
[DOI] 10.1172/jci.insight.151349.
[PMID] 34806648.
2021
CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII.
Molecular therapy : the journal of the American Society of Gene Therapy.
29(9):2660-2676
[DOI] 10.1016/j.ymthe.2021.04.034.
[PMID] 33940160.
2021
De‐coding genetic risk variants in type 1 diabetes
Immunology & Cell Biology.
99(5):496-508
[DOI] 10.1111/imcb.12438.
[PMID] 33483996.
2021
Editorial: Footprints of Immune Cells in the Type 1 Diabetic Pancreas.
Frontiers in endocrinology.
12
[DOI] 10.3389/fendo.2021.767012.
[PMID] 34721308.
2021
Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size.
Diabetes.
70(4):944-954
[DOI] 10.2337/db20-0995.
[PMID] 33441381.
2021
geneBasis: an iterative approach for unsupervised selection of targeted gene panels from scRNA-seq.
Genome biology.
22(1)
[DOI] 10.1186/s13059-021-02548-z.
[PMID] 34872616.
2021
Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis.
Diabetes.
70(4):932-943
[DOI] 10.2337/db20-0937.
[PMID] 33419759.
2021
Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex
Cell Reports.
37(9)
[DOI] 10.1016/j.celrep.2021.110071.
[PMID] 34852222.
2021
Infant T cells are developmentally adapted for robust lung immune responses through enhanced T cell receptor signaling
Science Immunology.
6(66)
[DOI] 10.1126/sciimmunol.abj0789.
[PMID] 34890254.
2021
Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness
Journal of Clinical Medicine.
10(8)
[DOI] 10.3390/jcm10081693.
[PMID] 33920038.
2021
Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report
Diabetes.
70(5):1123-1129
[DOI] 10.2337/db20-1103.
[PMID] 33632742.
2021
Lupus susceptibility gene Esrrg modulates regulatory T cells through mitochondrial metabolism
JCI Insight.
6(14)
[DOI] 10.1172/jci.insight.143540.
[PMID] 34156979.
2021
Overexpression of the PTPN22 Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T Cell Activation
The Journal of Immunology.
207(3):849-859
[DOI] 10.4049/jimmunol.2000708.
[PMID] 34301848.
2021
Reduced Follicular Regulatory T Cells in Spleen and Pancreatic Lymph Nodes of Patients With Type 1 Diabetes.
Diabetes.
70(12):2892-2902
[DOI] 10.2337/db21-0091.
[PMID] 34620616.
2021
SARS-CoV-2 infection generates tissue-localized immunological memory in humans
Science Immunology.
6(65)
[DOI] 10.1126/sciimmunol.abl9105.
[PMID] 34618554.
2021
Single-Cell RNA-seq of Human Myeloid-Derived Suppressor Cells in Late Sepsis Reveals Multiple Subsets With Unique Transcriptional Responses: A Pilot Study.
Shock (Augusta, Ga.).
55(5):587-595
[DOI] 10.1097/SHK.0000000000001671.
[PMID] 33021571.
2021
Strategies for durable β cell replacement in type 1 diabetes
Science.
373(6554):516-522
[DOI] 10.1126/science.abh1657.
[PMID] 34326233.
2021
TCR+/BCR+ dual-expressing cells and their associated public BCR clonotype are not enriched in type 1 diabetes.
Cell.
184(3):827-839.e14
[DOI] 10.1016/j.cell.2020.11.035.
[PMID] 33545036.
2021
The immuneML ecosystem for machine learning analysis of adaptive immune receptor repertoires.
Nature machine intelligence.
3(11):936-944
[DOI] 10.1038/s42256-021-00413-z.
[PMID] 37396030.
2021
The Immunoregulatory Role of the Signal Regulatory Protein Family and CD47 Signaling Pathway in Type 1 Diabetes.
Frontiers in immunology.
12
[DOI] 10.3389/fimmu.2021.739048.
[PMID] 34603322.
2021
Use of Induced Pluripotent Stem Cells to Build Isogenic Systems and Investigate Type 1 Diabetes.
Frontiers in endocrinology.
12
[DOI] 10.3389/fendo.2021.737276.
[PMID] 34858326.
2020
A Novel Mutation in Insulin-Like Growth Factor 1 Receptor (c.641-2A>G) Is Associated with Impaired Growth, Hypoglycemia, and Modified Immune Phenotypes.
Hormone research in paediatrics.
93(5):322-334
[DOI] 10.1159/000510764.
[PMID] 33113547.
2020
CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation.
Frontiers in immunology.
11
[DOI] 10.3389/fimmu.2020.02180.
[PMID] 33013915.
2020
CD70 Inversely Regulates Regulatory T Cells and Invariant NKT Cells and Modulates Type 1 Diabetes in NOD Mice
The Journal of Immunology.
205(7):1763-1777
[DOI] 10.4049/jimmunol.2000148.
[PMID] 32868408.
2020
Characterization of Proinsulin T Cell Epitopes Restricted by Type 1 Diabetes–Associated HLA Class II Molecules
The Journal of Immunology.
204(9):2349-2359
[DOI] 10.4049/jimmunol.1901079.
[PMID] 32229538.
2020
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.
Diabetes technology & therapeutics.
22(12):948-953
[DOI] 10.1089/dia.2020.0305.
[PMID] 32833543.
2020
Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes.
Diabetic medicine : a journal of the British Diabetic Association.
37(12):2160-2168
[DOI] 10.1111/dme.14361.
[PMID] 32634859.
2020
Human Regulatory T Cells From Umbilical Cord Blood Display Increased Repertoire Diversity and Lineage Stability Relative to Adult Peripheral Blood.
Frontiers in immunology.
11
[DOI] 10.3389/fimmu.2020.00611.
[PMID] 32351504.
2020
Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype In Vitro and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses.
Frontiers in immunology.
11
[DOI] 10.3389/fimmu.2020.574447.
[PMID] 33193362.
2020
Immunophenotyping reveals distinct subgroups of lupus patients based on their activated T cell subsets.
Clinical immunology (Orlando, Fla.).
221
[DOI] 10.1016/j.clim.2020.108602.
[PMID] 33007439.
2020
Innate inflammation drives NK cell activation to impair Treg activity.
Journal of autoimmunity.
108
[DOI] 10.1016/j.jaut.2020.102417.
[PMID] 32035746.
2020
Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis
Diabetes.
69(3):413-423
[DOI] 10.2337/db19-0942.
[PMID] 31826866.
2020
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
Diabetes Care.
43(1):5-12
[DOI] 10.2337/dc19-0880.
[PMID] 31753960.
2020
Oral therapy with colonization factor antigen I prevents development of type 1 diabetes in Non-obese Diabetic mice
Scientific Reports.
10(1)
[DOI] 10.1038/s41598-020-62881-4.
[PMID] 32273533.
2020
Synchronization of the Normal Human Peripheral Immune System: A Comprehensive Circadian Systems Immunology Analysis
Scientific Reports.
10(1)
[DOI] 10.1038/s41598-019-56951-5.
[PMID] 31959869.
2020
Teaching Type 1 Diabetes: Creating Stakeholder Engagement in Biomedical Careers Through Undergraduate Research Curriculum
Medical Science Educator.
30(1):69-73
[DOI] 10.1007/s40670-019-00877-0.
[PMID] 34457640.
2019
A checkpoint on innate myeloid cells in pulmonary arterial hypertension.
Pulmonary circulation.
9(1)
[DOI] 10.1177/2045894018823528.
[PMID] 30562157.
2019
A Mutation in the Transcription Factor Foxp3 Drives T Helper 2 Effector Function in Regulatory T Cells.
Immunity.
50(2):362-377.e6
[DOI] 10.1016/j.immuni.2018.12.016.
[PMID] 30709738.
2019
An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes
Journal of Experimental Medicine.
216(11):2479-2491
[DOI] 10.1084/jem.20190430.
[PMID] 31467037.
2019
Crossreactive public TCR sequences undergo positive selection in the human thymic repertoire.
The Journal of clinical investigation.
129(6):2446-2462
[DOI] 10.1172/JCI124358.
[PMID] 30920391.
2019
Dual-Sized Microparticle System for Generating Suppressive Dendritic Cells Prevents and Reverses Type 1 Diabetes in the Nonobese Diabetic Mouse Model.
ACS biomaterials science & engineering.
5(5):2631-2646
[DOI] 10.1021/acsbiomaterials.9b00332.
[PMID] 31119191.
2019
Islet-immune interactions in type 1 diabetes: the nexus of beta cell destruction.
Clinical and experimental immunology.
198(3):326-340
[DOI] 10.1111/cei.13349.
[PMID] 31309537.
2019
Metformin Inhibits the Type 1 IFN Response in Human CD4+ T Cells
The Journal of Immunology.
203(2):338-348
[DOI] 10.4049/jimmunol.1801651.
[PMID] 31160534.
2019
Pleiotropic roles of the insulin-like growth factor axis in type 1 diabetes
Current Opinion in Endocrinology Diabetes and Obesity.
26(4):188-194
[DOI] 10.1097/MED.0000000000000484.
[PMID] 31145130.
2019
Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances
Diabetes.
68(7):1366-1379
[DOI] 10.2337/db19-0119.
[PMID] 31221801.
2019
The human body at cellular resolution: the NIH Human Biomolecular Atlas Program
Nature.
574(7777):187-192
[DOI] 10.1038/s41586-019-1629-x.
[PMID] 31597973.
2018
Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling
Scientific Reports.
8(1)
[DOI] 10.1038/s41598-018-22574-5.
[PMID] 29540798.
2018
Clinical Applications of Regulatory T cells in Adoptive Cell Therapies.
Cell & gene therapy insights.
4(1):405-429
[DOI] 10.18609/cgti.2018.042.
[PMID] 34984106.
2018
Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.
Current diabetes reports.
18(10)
[DOI] 10.1007/s11892-018-1066-5.
[PMID] 30168021.
2018
Inhibition of glucose metabolism selectively targets autoreactive follicular helper T cells
Nature Communications.
9(1)
[DOI] 10.1038/s41467-018-06686-0.
[PMID] 30348969.
2018
Myeloid-Derived Suppressor Cells and Pulmonary Hypertension
International Journal of Molecular Sciences.
19(8)
[DOI] 10.3390/ijms19082277.
[PMID] 30081463.
2017
Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes.
Frontiers in immunology.
8
[DOI] 10.3389/fimmu.2017.01313.
[PMID] 29123516.
2017
Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.
Molecular therapy. Methods & clinical development.
4:178-191
[DOI] 10.1016/j.omtm.2016.12.003.
[PMID] 28345003.
2017
Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.
Cancer research.
77(3):672-683
[DOI] 10.1158/0008-5472.CAN-16-1765.
[PMID] 27864347.
2017
Interferon-γ Limits Diabetogenic CD8+ T-Cell Effector Responses in Type 1 Diabetes.
Diabetes.
66(3):710-721
[DOI] 10.2337/db16-0846.
[PMID] 27920091.
2017
Isogenic Cellular Systems Model the Impact of Genetic Risk Variants in the Pathogenesis of Type 1 Diabetes.
Frontiers in endocrinology.
8
[DOI] 10.3389/fendo.2017.00276.
[PMID] 29093700.
2017
Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults.
Frontiers in immunology.
8
[DOI] 10.3389/fimmu.2017.00655.
[PMID] 28659913.
2017
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.
Frontiers in immunology.
8
[DOI] 10.3389/fimmu.2017.01844.
[PMID] 29379498.
2017
Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-07172-1.
[PMID] 28761107.
2017
Serum Trypsinogen Levels in Type 1 Diabetes.
Diabetes care.
40(4):577-582
[DOI] 10.2337/dc16-1774.
[PMID] 28115475.
2017
T Cell Receptor Profiling in Type 1 Diabetes.
Current diabetes reports.
17(11)
[DOI] 10.1007/s11892-017-0946-4.
[PMID] 29022222.
2017
T cells display mitochondria hyperpolarization in human type 1 diabetes.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-11056-9.
[PMID] 28883439.
2017
Type 1 Interferons Potentiate Human CD8+ T-Cell Cytotoxicity Through a STAT4- and Granzyme B-Dependent Pathway.
Diabetes.
66(12):3061-3071
[DOI] 10.2337/db17-0106.
[PMID] 28877912.
2016
Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Diabetes.
65(12):3765-3775
[PMID] 27669730.
2016
Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.
Clinical and experimental immunology.
183(3):350-7
[DOI] 10.1111/cei.12731.
[PMID] 26462724.
2016
The Lupus Susceptibility Gene Pbx1 Regulates the Balance between Follicular Helper T Cell and Regulatory T Cell Differentiation
The Journal of Immunology.
197(2):458-469
[DOI] 10.4049/jimmunol.1502283.
[PMID] 27296664.
2016
Tissue distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes.
JCI insight.
1(20)
[DOI] 10.1172/jci.insight.88242.
[PMID] 27942583.
2015
Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
The Journal of clinical investigation.
125(1):448-55
[DOI] 10.1172/JCI78492.
[PMID] 25500887.
2015
Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.
Diabetes.
64(11):3873-84
[DOI] 10.2337/db15-0164.
[PMID] 26185279.
2015
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
The Journal of Immunology.
195(1):145-155
[DOI] 10.4049/jimmunol.1402381.
[PMID] 25994968.
2015
Normalization of CD4+ T cell metabolism reverses lupus.
Science translational medicine.
7(274)
[DOI] 10.1126/scitranslmed.aaa0835.
[PMID] 25673763.
2014
Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres.
Journal of materials chemistry. B.
2(17):2562-2574
[PMID] 24778809.
2014
Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia.
Molecular therapy. Methods & clinical development.
1
[PMID] 25364772.
2014
Mir-125A-5P Is Up-Regulated in Un-Functional Cd4+Foxp3+T Regulatory Cells Deriving From Pancreatic Lymph Nodes of Patients With Type 1 Diabetes and Targets C-C Chemokine Receptor Type 2
.
57(1)
2013
Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
19(7):1126-9
[DOI] 10.1016/j.bbmt.2013.04.011.
[PMID] 23611977.
2013
Ex Vivo Expanded Treg Suppress Inhibitor Formation in Protein and Gene Therapies for Hemophilia
Molecular Therapy.
21
2013
Faculty Opinions recommendation of In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[DOI] 10.3410/f.717991564.793473379.
2013
Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
The Journal of clinical investigation.
123(12):5310-8
[DOI] 10.1172/JCI70314.
[PMID] 24231351.
2013
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
Cancer immunology, immunotherapy : CII.
62(4):737-46
[DOI] 10.1007/s00262-012-1380-8.
[PMID] 23223899.
2013
Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.
Immunotherapy.
5(12):1357-66
[DOI] 10.2217/imt.13.130.
[PMID] 24283846.
2013
The autoimmune disease-associated SNP rs917997 of IL18RAP controls IFNγ production by PBMC.
Journal of autoimmunity.
44:8-12
[DOI] 10.1016/j.jaut.2013.06.001.
[PMID] 23891168.
2012
Autologous regulatory T cells for the treatment of type 1 diabetes.
Current diabetes reports.
12(5):623-32
[DOI] 10.1007/s11892-012-0304-5.
[PMID] 22843491.
2012
Central role for interleukin-2 in type 1 diabetes.
Diabetes.
61(1):14-22
[DOI] 10.2337/db11-1213.
[PMID] 22187370.
2012
Modulation of T Cell Receptor and Interleukin-2 Receptor Signaling in Human Primary Cd4(+) T Cells
Journal of Immunology.
188
2012
Serum levels of soluble CD25 as a marker for hepatocellular carcinoma.
Oncology letters.
4(4):840-846
[PMID] 23205111.
2012
Suppression of Inhibitor Formation in Protein and Gene Therapy for Hemophilia Using Ex Vivo Expanded Treg
Blood.
120
2011
Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide.
Diabetes care.
34(12):2567-9
[DOI] 10.2337/dc11-1406.
[PMID] 22011412.
2011
Defective response of CD4(+) T cells to retinoic acid and TGFβ in systemic lupus erythematosus.
Arthritis research & therapy.
13(3)
[DOI] 10.1186/ar3387.
[PMID] 21708033.
2011
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.
Journal of immunology (Baltimore, Md. : 1950).
186(7):3918-26
[DOI] 10.4049/jimmunol.1003099.
[PMID] 21368230.
2011
Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.
PloS one.
6(1)
[DOI] 10.1371/journal.pone.0015868.
[PMID] 21253593.
2010
Human Antigen-Specific Regulatory T Cells Generated By T Cell Receptor Gene Transfer
PLoS One.
5(7)
[DOI] 10.1371/journal.pone.0011726.
[PMID] 20668510.
2009
Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.
Diabetes care.
32(11):2041-6
[DOI] 10.2337/dc09-0967.
[PMID] 19875605.
2009
Expansion of human regulatory T-cells from patients with type 1 diabetes.
Diabetes.
58(3):652-62
[DOI] 10.2337/db08-1168.
[PMID] 19074986.
2009
Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation.
PloS one.
4(11)
[DOI] 10.1371/journal.pone.0007980.
[PMID] 19956753.
2008
Autologous umbilical cord blood infusion for type 1 diabetes.
Experimental hematology.
36(6):710-5
[DOI] 10.1016/j.exphem.2008.01.009.
[PMID] 18358588.
2008
CFTR mutations impart elevated immune reactivity in a murine model of cystic fibrosis related diabetes.
Cytokine.
44(1):154-9
[DOI] 10.1016/j.cyto.2008.07.468.
[PMID] 18778952.
2008
Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency.
Annals of the New York Academy of Sciences.
1150:152-6
[DOI] 10.1196/annals.1447.049.
[PMID] 19120286.
2008
Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation.
Diabetes.
57(2):405-14
[PMID] 18039815.
2008
Suppression by CD4+CD25+ regulatory T cells is dependent on expression of heme oxygenase-1 in antigen-presenting cells.
The American journal of pathology.
173(1):154-60
[DOI] 10.2353/ajpath.2008.070963.
[PMID] 18511516.
2007
Assessing the in vitro suppressive capacity of regulatory T cells.
Immunological investigations.
36(5-6):607-28
[PMID] 18161521.
2007
Characterization of HKE2: an ancient antigen encoded in the major histocompatibility complex.
Tissue antigens.
69(2):181-8
[PMID] 17257322.
2007
Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.
Nature genetics.
39(9):1074-82
[PMID] 17676041.
2007
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.
Diabetes.
56(3):604-12
[PMID] 17327427.
2007
Treg in type 1 diabetes.
Cell biochemistry and biophysics.
48(2-3):165-75
[PMID] 17709886.
2006
A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome.
Pediatric nephrology (Berlin, Germany).
21(5):603-10
[PMID] 16525836.
2006
Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis.
Journal of immunology (Baltimore, Md. : 1950).
177(11):7943-9
[PMID] 17114466.
2006
PANDER-induced cell-death genetic networks in islets reveal central role for caspase-3 and cyclin-dependent kinase inhibitor 1A (p21).
Gene.
369:134-41
[PMID] 16412588.
2005
An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+CD25+ regulatory T cells.
Journal of immunology (Baltimore, Md. : 1950).
174(9):5181-6
[PMID] 15843512.
2005
Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes.
Diabetes.
54(5):1407-14
[PMID] 15855327.
2004
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes.
Nature genetics.
36(8):837-41
[PMID] 15247916.
2004
Adiponectin and leptin concentrations may aid in discriminating disease forms in children and adolescents with type 1 and type 2 diabetes.
Diabetes care.
27(8):2010-4
[PMID] 15277432.
2004
Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse.
The American journal of pathology.
165(3):1045-53
[PMID] 15331427.
2004
Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.
Gene therapy.
11(3):233-40
[PMID] 14737082.
2004
Presence of diabetes-inhibiting, glutamic acid decarboxylase-specific, IL-10-dependent, regulatory T cells in naive nonobese diabetic mice.
Journal of immunology (Baltimore, Md. : 1950).
173(11):6777-85
[PMID] 15557171.
2004
Radial artery tonometry demonstrates arterial stiffness in children with type 1 diabetes.
Diabetes care.
27(12):2911-7
[PMID] 15562206.
2003
Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice.
Diabetes.
52(3):708-16
[PMID] 12606512.
2003
Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion.
Journal of immunology (Baltimore, Md. : 1950).
171(5):2270-8
[PMID] 12928371.
Augmented TCR-mediated signaling in infant T cells enables robust responses to respiratory virus infection
.
[DOI] 10.21203/rs.3.rs-229370/v1.
Grants
Sep 2024
ACTIVE
Restoration of immune regulation in type 1 diabetes through the synergistic action of insulin-like growth factor-1 and interleukin-2
Role: Principal Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Sep 2024
ACTIVE
Fc? Receptor-Mediated Pharmacogenomics of Antibody Therapies in Type 1 Diabetes.
Role: Other
Funding: NATL INST OF HLTH NIDDK
Aug 2024
ACTIVE
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Administered Subcutaneously to Patients with Type 1 Diabetes Mellitus (TN-27)
Role: Principal Investigator
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH NIDDK
Nov 2023
ACTIVE
Interrogating the role of T1D-associated genetic variants on T cell phenotype and function
Role: Other
Funding: AMER DIABETES ASSOCIATION
Oct 2023
ACTIVE
Network for Pancreatic Organ Donors – nPOD
Role: Co-Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Sep 2023
– Aug 2024
T and B cell Receptor Atlas Across Tissues and Stages of Type 1 Diabetes
Role: Principal Investigator
Funding: UNIV OF COLORADO DENVER & ANSCHUTZ MED
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Jun 2023
ACTIVE
Immune Function and the Progression to Type 1 Diabetes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Feb 2023
ACTIVE
The CD226 costimulatory axis in type 1 diabetes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jan 2023
ACTIVE
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Dec 2022
ACTIVE
Human Atlas of Neonatal Development and Early Life-Immunity (HANDEL-I) continuation
Role: Principal Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Sep 2022
– May 2024
Engineering islet-like organoids from gastric stem cells for T1D cell replacement therapy
Role: Principal Investigator
Funding: CORNELL UNIV
via NATL INST OF HLTH NIDDK
May 2022
– May 2023
Multi-modal single cell analysis for investigation of T1D pathogenesis
Role: Other
Funding: NATL INST OF HLTH NIDDK
May 2022
– Apr 2023
Impact of T1D Risk Alleles on Pancreatic Islet Gene Expression in TIGER and PANC-DB Studies
Role: Other
Funding: THE SUGAR SCIENCE
May 2022
– Apr 2023
Regulatory T-cells Engineering and Functionality Validation
Role: Principal Investigator
Funding: IMMUNOCORE LIMITED
Mar 2022
ACTIVE
Evaluating a Precision Medicine Approach Toward Anti-Thymocyte Globulin (ATG) Treatment in Type 1 Diabetes
Role: Other
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Feb 2022
– Mar 2023
CD226 inhibition to prevent regulatory T cell dysfunction in type 1 diabetes
Role: Other
Funding: DIABETES RESEARCH CONNECTION
Aug 2021
ACTIVE
Human Pancreas Analysis Program for Type 1 Diabetes – HPAP-T1D
Role: Co-Investigator
Funding: UNIV OF PENNSYLVANIA
via NATL INST OF HLTH NIDDK
Jul 2021
ACTIVE
Development of a Predictive Response Signature to Anti-Thymocyte Globulin in Type 1 Diabetes
Role: Other
Funding: NATL INST OF HLTH NIDDK
Jul 2021
ACTIVE
F30 (Francis) Thymic PD-1 blockade mediates the anti-tumor immune response in pediatric high-grade glioma
Role: Other
Funding: NATL INST OF HLTH NCI
May 2021
ACTIVE
Generation of Islet Specific T Follicular Regulatory Like Cells for Autologous Cell Therapy of Type 1 Diabetes
Role: Other
Funding: NATL INST OF HLTH NIDDK
May 2021
– Sep 2023
The Network for Pancreatic Organ donors with Diabetes (nPOD) : A Collaborative Type 1 Diabetes Research Project
Role: Co-Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Apr 2021
– Jun 2022
Human Islet Research Enhancement Center for the Human Islet Research Network: "The SIRP:CD47 Signaling Pathway in Pancreatic ?-Cell Survival"
Role: Other
Funding: CITY OF HOPE
via NATL INST OF HLTH NIDDK
Mar 2021
– Jul 2023
Immunocore ImmTAAI technology and its potential use to treat type 1 diabetes autoimmunity
Role: Co-Project Director/Principal Investigator
Funding: IMMUNOCORE LIMITED
Feb 2021
ACTIVE
Type 1 diabetes genetic risk scores for the diagnosis of diabetes type in children of diverse racial and ethnic background
Role: Principal Investigator
Funding: BAYLOR COLLEGE OF MEDICINE
via NATL INST OF HLTH NIDDK
Apr 2020
ACTIVE
Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension
Role: Other
Funding: NATL INST OF HLTH NHLBI
Apr 2020
ACTIVE
The Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
Role: Project Manager
Funding: NATL INST OF HLTH NIGMS
Feb 2020
ACTIVE
TrialNet Clinical Center infrastructure support services
Role: Co-Investigator
Funding: UNIV OF SOUTH FLORIDA
via NATL INST OF HLTH NIDDK
Feb 2020
ACTIVE
Human Atlas of Neonatal Developmental and Early Life Pancreas / Immunity (HANDEL)-P/I Continuation
Role: Co-Project Director/Principal Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Sep 2019
– Aug 2021
Engineered Tregs to block autoantibody development and progression of type 1 diabetes
Role: Principal Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Aug 2019
ACTIVE
Engineering a Human Microphysiological System for the Characterization of Islet-Immune Interactions
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Aug 2019
– Jul 2021
Engineering a Human Microphysiological System for the Characterization of Islet-Immune Interactions
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jun 2019
– Sep 2020
Amendment 2 – Genetic Data Analysis
Role: Principal Investigator
Funding: ADAPTIVE BIOTECHNOLOGIES
Jun 2019
– Aug 2020
Single cell sequencing for islet-reactive T cell clonotype and transcript signatures
Role: Principal Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Mar 2019
– Jul 2019
Safety & Efficacy of Imatinib for Preserving Beta-cell Function in New-Onset T1D
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via BREAKTHROUGH T1D – formerly JDRF Intl
Oct 2018
– Sep 2022
T cell receptor sequencing in type 1 diabetes – biomarker discovery and technology development
Role: Principal Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Sep 2018
– Jun 2023
A 3D Tissue Map of the Human Lymphatic System
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jul 2018
– Jun 2019
The impacts of co-stimulatory molecules CD226 and TIGIT on T1D development
Role: Other
Funding: AMER DIABETES ASSOCIATION
Jun 2018
– May 2023
Immune Function and the Progression to Type 1 Diabetes
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jun 2018
– May 2022
Characterization of SLE-susceptibility loci on mouse chromosome 1
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jun 2018
– Jun 2019
Characterization of T cell Autoreactivity in Type 1 Diabetes
Role: Faculty
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Apr 2018
– Dec 2021
Human Atlas of Neonatal Development and Early-Life Immunity (HANDEL-I)
Role: Principal Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Jan 2018
– Sep 2023
Collaborative Type 1 Diabetes Research Project: The Network for Pancreatic Organ donors with Diabetes (nPOD)
Role: Co-Investigator
Funding: HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Jan 2018
– Dec 2021
An Imputation-Consistency Algorithm for Biomedical Complex Data Analysis
Role: Faculty
Funding: PURDUE UNIV
via NATL INST OF HLTH NIGMS
Aug 2017
– Jul 2018
Low-Dose IL-2 in Established T1D
Role: Co-Investigator
Funding: UNIV OF MIAMI
via NATL INST OF HLTH NIAID
Jul 2017
– Jun 2018
Islet-reactive TCR clones in humanized mice generated with type 1 diabetes patient
Role: Principal Investigator
Funding: BECKMAN RES INST OF CITY OF HOPE
via NATL INST OF HLTH NIDDK
Jun 2017
– May 2020
Delivery of biomaterial-conjugated regulatory T Cells for the amelioration of Type 1 Diabetes
Role: Principal Investigator
Funding: ONEVAX
via NATL INST OF HLTH NIAID
Apr 2017
– Mar 2021
Advanced Liver 3-D Tissue Models for Drug Development Applications to Support Toxicology, Drug Metabolism, Target ID & Pharmacology
Role: Faculty
Funding: ADV REGENERATIVE MANUFACTURING INST
via US ARMY RESEARCH LABORATORY
Mar 2017
– Mar 2019
Biomaterial-based delivery of Interleukin-2 to Regulatory T Cells for the amelioration of Type 1 diabetes
Role: Principal Investigator
Funding: ONEVAX
via NATL INST OF HLTH
Jan 2017
– Dec 2017
Impacts of co-stimulation molecules CD226 and TIGIT on NK cell immunoregulation and function during Type 1 diabetes
Role: Other
Funding: AMER DIABETES ASSOCIATION
Sep 2016
– Jun 2019
Functional Interrogation of Non-Coding Type 1 Diabetes Risk Variants in Human Immune Cells and Beta Cells
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via NATL INST OF HLTH NIDDK
Aug 2016
– Jul 2019
Insulin Specific T and B cells in Type 1 Diabetes
Role: Co-Investigator
Funding: UNIV OF COLORADO DENVER & ANSCHUTZ MED
via NATL INST OF HLTH NIDDK
Jun 2016
– Nov 2019
Clinical Trial Planning Grant for Treg Therapy in Type I Diabetes
Role: Co-Investigator
Funding: CORD BLOOD REGISTRY
Jun 2016
– May 2019
Disruption of T cell tolerance in type 1 diabetes: Specificity and repertoire of Tregs in T1D
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via NATL INST OF HLTH NIAID
Jun 2016
– Apr 2018
T cell therapy against factor VIII inhibitors
Role: Other
Funding: BAYER HEALTHCARE PHARMACEUTICALS
May 2016
– Apr 2018
Altered Immunometabolic Associations With Type 1 Diabetes Clinical Status and Genetic Risk.
Role: Principal Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Apr 2016
– Feb 2021
The CD226 amd TIGIT costimulatory Axis in Type 1
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Feb 2016
– Jan 2017
Characterization and in silico reconstruction of TCRs for modeling autoreactive T cells in T1D
Role: Principal Investigator
Funding: BECKMAN RES INST OF CITY OF HOPE
via NATL INST OF HLTH NIDDK
Jan 2016
– Dec 2018
ELUCIDATING THE IMMUNOREGULATORY ROLES OF TIGIT AND CD226DURING T1D
Role: Principal Investigator
Funding: AMER DIABETES ASSOCIATION
Jan 2016
– Dec 2016
Determine the influence of IL-12 and IL-18 signaling on Treg activity
Role: Principal Investigator
Funding: AMER DIABETES ASSOCIATION
Jan 2015
– Jul 2016
Cord Blood Expansion of Regulatory T cells
Role: Principal Investigator
Funding: CBR SYSTEMS
Nov 2014
– Dec 2017
The George S. Eisenbarth nPOD Award for Team Science
Role: Principal Investigator
Funding: UNIV OF MIAMI
via HELMSLEY CHARITABLE TRUST, LEONA & HARRY
Sep 2014
– Jun 2019
Genetic Regulation of Human Beta Cell Destruction
Role: Project Manager
Funding: NATL INST OF HLTH NIDDK
Sep 2013
– Jun 2016
Minimizing Leukemia Relapse: A Phase I, Dose Escalation Study of Decitabine in High Risk Pediatric and Young Adult Leukemia Post Allogeneic Stem Cell Transplantation
Role: Project Manager
Funding: HYUNDAI HOPE ON WHEELS
Jul 2013
– Jun 2016
Influence of IL-12 and IL-18 on immunoregulation and type 1 diabetes pathogenesis
Role: Principal Investigator
Funding: AMER DIABETES ASSOCIATION
May 2013
– Jun 2018
Characterization of SLE-susceptibility loci on mouse chromosome 1
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
May 2013
– Jun 2018
Immune Function and the Progression to Type 1 Diabetes
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
May 2012
– Apr 2017
Investigating Human Autoreactive T Cell Responses in Humanized Mice
Role: Principal Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Contact Details
Phones:
- Business:
- (352) 273-9255
Emails:
- Business:
- tbrusko@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100275
GAINESVILLE FL 32610 - Business Street:
-
BMSB J-583
GAINESVILLE FL 32610